arrow
F

Felix Y. Feng

University of California San Francisco
H指数:109
被引数:5.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

基因组规模CRISPR筛选确定PTGES3为晚期前列腺癌雄激素受体功能的直接调节因子

2025-11-050
OAAI
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

cfDNA片段组学指标分析与商业靶向测序面板

2025-10-140
OAAI
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

通过调节PPARγ通路上调NECTIN4,并增强膀胱癌中嵌合抗原受体(CAR)T细胞疗法。Nat. Commun. 16 (1), 8215

2025-09-100
OAAI
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性

Cell
IF42.5
2025-08-260
OAAI
Leveraging sequences missing from the human genome to diagnose cancer

利用缺失于人类基因组中的序列来诊断癌症

2025-08-210
OA
Long term results of NRG Oncology RTOG 9601, a randomized trial of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy post prostatectomy

NRG Oncology RTOG 9601试验的长期结果,该试验是一项随机试验,研究在前列腺切除术后接受挽救性前列腺床放射治疗的患者中,使用或不使用抗雄激素药物(AAT)的放射治疗效果。

2025-08-050
PRE
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial

局部高危前列腺癌的转录组学分析改善了预后判断,并确定了在NRG肿瘤学/RTOG 0521 III期试验中,将多西他赛添加到根治性放疗联合雄激素抑制治疗中获益。

2025-07-170
OAAI
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

2025-07-070
OAAI
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial

根治性前列腺切除术后的辅助治疗中基因表达分类器检测的影响:G-MINOR前瞻性随机集群交叉试验

2025-02-011
PRE
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer
2025-01-010
PRE
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate

规范雄激素反应元件基序是前列腺中的肿瘤抑制调节元件

2024-12-130
OAAI
Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial (vol 117, pg 370, 2023)
2024-12-010
PRE
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials

高风险前列腺癌中多模式人工智能生物标志物的个体患者水平数据的荟萃分析: 来自六项NRG/RTOG 3期随机试验的结果

2024-10-010
OA
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
2024-10-010
OAAI
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

NRG/RTOG 9902 3期试验中基于数字病理学的多模态人工智能架构的外部验证

2024-10-012
OA
Clinical cell-surface targets in metastatic and primary solid cancers
2024-09-240
OA